Quantcast

Latest Thalidomide Stories

2009-06-01 07:30:00

Carfilzomib Achieves 26 Percent Clinical Benefit Response Rate in Phase 2 Trial of Relapsed and Refractory Multiple Myeloma Patients - Proteolix Expands Trial ORLANDO, Fla. and SOUTH SAN FRANCISCO, Calif., June 1 /PRNewswire/ -- Proteolix, Inc. today presented results from the company's most advanced clinical trial of single-agent carfilzomib demonstrating anti-cancer activity and progression-free survival in patients with relapsed and refractory multiple myeloma. Carfilzomib is the first...

2009-05-15 07:30:00

Results from Phase 2 Clinical Trials of Carfilzomib in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Featured in Oral Presentations SOUTH SAN FRANCISCO, May 15 /PRNewswire/ -- Proteolix, Inc. today announced that data from clinical trials of carfilzomib in multiple myeloma and advanced solid tumors will be presented at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 29 - June 2, 2009 in Orlando, Florida. Carfilzomib is the first in...

698df1a77757c5524a9f86edad91e8851
2009-04-15 11:51:21

Major impact envisioned for pharmaceutical, food, agriculture industries Scientists studying how marine bacteria move have discovered that a sharp variation in water current segregates right-handed bacteria from their left-handed brethren, impelling the microbes in opposite directions. This finding and the possibility of quickly and cheaply implementing the segregation of two-handed objects in the laboratory could have a big impact on industries like the pharmaceutical industry, for which the...

2009-04-12 08:50:16

Thalidomide victims once snubbed by the German government are being offered compensation for birth defects caused by the drug, officials say. The German family ministry has announced it will temporarily waive a 26-year-old ban on considering thalidomide relief claims from foreign countries until the end of 2010, thus enabling victims from around the world to collect damages on the drug formerly made by the German company Grunenthal, The Sunday Times of London reported. Germany since 1983 has...

2009-02-26 07:29:00

New subset analysis of bortezomib-relapsed patient population demonstrates 55% overall response rate and extended time to progression NEW YORK, Feb. 26 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced updated clinical results from an ongoing Phase 1/2 study of KRX-0401 (perifosine) in combination with bortezomib (+/- dexamethasone) in patients with relapsed/refractory multiple myeloma. The data, which was presented earlier today in a poster featured at...

2009-02-01 13:47:43

Thalidomide victims in Britain say the government is denying them financial aid as they age and their health worsens. It's estimated more than 450 people whose mothers took thalidomide during pregnancy are nearing 50 and suffering physical breakdowns, The Sunday Times of London reported. Thousands of British mothers were prescribed thalidomide as a cure for morning sickness, and gave birth to babies who then died or grew up with drastically stunted arms and fingers and no shoulder joints....

2008-12-09 09:00:00

SOUTH SAN FRANCISCO, Calif., Dec. 9 /PRNewswire/ -- Proteolix, Inc. today announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma. Carfilzomib is the first in a new class of specific proteasome inhibitors being developed by Proteolix for the treatment of hematologic malignancies and solid tumors. Sundar Jagannath, M.D., Chief of the...

2008-12-09 06:00:00

ROCKVILLE, Md., Dec. 9 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has initiated a Phase 1 study of ENMD-2076 in refractory multiple myeloma patients. The study will be conducted at the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana. Dr. Sherif Farag, Associate Professor, Department of Medicine, will...

2008-12-08 16:46:00

SAN FRANCISCO, Dec. 8 /PRNewswire/ -- Millennium: The Takeda Oncology Company today reported updated results from two large, multi-center, randomized Phase III clinical trials of VELCADE based combinations for the induction treatment of transplant-eligible patients with previously untreated multiple myeloma (MM). Prolonged progression-free survival (PFS) was observed in one study comparing VELCADE and dexamethasone (VcD) with vincristine, adriamycin and dexamethasone (VAD), as well as in...

2008-11-06 15:00:28

The International Myeloma Foundation (IMF)--supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians--today called for all patients to have access to the newest pharmaceuticals making life-changing advances in the treatment of myeloma. REVLIMID(R), THALOMID(R) (global thalidomide) and VELCADE(R), known collectively as the "novel therapies," have extended survival and improved quality of life for patients with the blood...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related